Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Sedation in Endoscopic Retrograde Cholangiopancreatography (ERCP) With or Without Opioids

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Argyro Fassoulaki, University of Athens
ClinicalTrials.gov Identifier:
NCT01304342
First received: February 24, 2011
Last updated: August 2, 2013
Last verified: March 2012
  Purpose

Addition of fentanyl or remifentanil to the propofol produced sedation for scheduled ERCP will decrease the propofol requirements for predetermined sedation levels (as shown by Bispectral Index Monitor (BIS) monitor), will be associated with faster recovery monitored by Ramsay's and Observer's Assessment of Alertness/Sedation (OAAS) scores and BIS, less postoperative pain (assessed by Visual Analogue Scale=VAS) and less early cognitive impairment after sedation (as assessed by the MiniMental test).


Condition Intervention
Chronic Pain
Drug: Remifentanil
Drug: Fentanyl
Drug: Normal saline

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effect of Intranasal Fentanyl Versus Remifentanil Infusion on Propofol Requirements During Elective Therapeutic ERCP, as Well on the Recovery, Pain, and Early Cognitive Function: A Randomized Control Trial

Resource links provided by NLM:


Further study details as provided by University of Athens:

Primary Outcome Measures:
  • Propofol requirements [ Time Frame: 30 min, 60 min and if not full recovery 120 min ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Speed of recovery [ Time Frame: 30, 60 and 120 min ] [ Designated as safety issue: Yes ]
  • postoperative pain [ Time Frame: 30, 60, and 120 minutes ] [ Designated as safety issue: Yes ]
  • early cognitive function [ Time Frame: 30, 60, and 120 minutes ] [ Designated as safety issue: Yes ]
  • patient satisfaction [ Time Frame: 30, 60, and 120 minutes ] [ Designated as safety issue: Yes ]
  • endoscopist satisfaction [ Time Frame: 30, 60, and 120 minutes ] [ Designated as safety issue: Yes ]

Enrollment: 180
Study Start Date: February 2011
Study Completion Date: July 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Remifentanil
Remifentanil 1 microgram/kg/h along with propofol infusion
Drug: Remifentanil
1 microgram/kg/h, continuous infusion, 5 min before and during the ERCP
Other Name: Ultiva
Active Comparator: Fentanyl
Fentanyl 200 micrograms intranasally
Drug: Fentanyl
Intranasal fentanyl 200 micrograms 5 min before the ERCP
Placebo Comparator: Normal saline
Normal saline intravenously and intranasally
Drug: Normal saline
Normal saline intravenously and intranasally

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   50 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients both sexes
  • ASA I-III
  • aged between 45 and 75 years old
  • scheduled for interventional ERCP

Exclusion Criteria:

  • patients receiving opioids or other analgesics, sedatives, hypnotics
  • allergic to drugs used in the study protocol
  • alcoholism
  • refuse to sign the informed consent and chronic pain
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01304342

Locations
Greece
Department of Anesthesiology, Aretaieio Hospital
Athens, Greece, 11528
Sponsors and Collaborators
University of Athens
  More Information

No publications provided

Responsible Party: Argyro Fassoulaki, MD, PhD, DEAA, University of Athens
ClinicalTrials.gov Identifier: NCT01304342     History of Changes
Other Study ID Numbers: M-17, M-18/21-12-2010
Study First Received: February 24, 2011
Last Updated: August 2, 2013
Health Authority: Greece: Ethics Committee

Keywords provided by University of Athens:
Propofol
remifentanil
fentanyl
ERCP
Quality of sedation
recovery
satisfaction
respiratory depression

Additional relevant MeSH terms:
Chronic Pain
Nervous System Diseases
Neurologic Manifestations
Pain
Signs and Symptoms
Fentanyl
Remifentanil
Adjuvants, Anesthesia
Analgesics
Analgesics, Opioid
Anesthetics
Anesthetics, General
Anesthetics, Intravenous
Central Nervous System Agents
Central Nervous System Depressants
Hypnotics and Sedatives
Narcotics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014